A Phase 2 interventional study of Trivalent influenza virus vaccine live, intranasal in Healthy, sponsored by MedImmune LLC. Completed at 16 sites in United States. Open to participants aged 6 Months to 59 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-24.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing FluMist in Influenza, Human — 4 open to participants now, 7 under way, none of them phase 3. FluMist · Influenza, Human.
Among the 37 studies testing FluMist in Influenza, Human, this one is the 13th largest by enrollment, is one of 2 that started in 2006, is the only one in phase 2, and was the 11th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →4 of the 37 studies testing FluMist in Influenza, Human are open now, in 3 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18–40 · Healthy volunteers
Imperial College London · Sites in United Kingdom
Ages 18–55 · Healthy volunteers
Changchun BCHT Biotechnology Co. · Sites in China
Ages 3–17 · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 6 Months to 59 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 2 · Phase 3 4 · Phase 4 21
First in 1998; this study’s year is marked. 2 started in 2006.
This study's enrollment of 200 is below the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 72 across the 37 interventional studies. Of the 29 that completed or were terminated, 15 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 37 have an industry lead sponsor. The 10 most frequent:
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
45 studies in Influenza, Human by AstraZeneca: 1 open now, 2 under way, 1 of them phase 3. Of 41 finished, 16 (39%) have results posted.
Among the 45 studies in Influenza, Human by AstraZeneca, this one is the 27th largest by enrollment of the 41 interventional ones that give a count, is the only one that started in 2006, is one of 11 in phase 2, and was the 23rd registered.
AstraZeneca’s Influenza, Human studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 37 studies testing FluMist in Influenza, Human, from their registry updates:
Among AstraZeneca’s 45 in Influenza, Human:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Open label, single arm, multicenter study of the shedding and safety of a single dose of trivalent, influenza virus vaccine live, intranasal in children 6 to \< 60 months of age, with 28-day shedding follow-up and 180-day safety follow-up.
This was a Phase 2, open-label, single-arm, multicenter study designed to evaluate vaccine virus shedding and safety of trivalent influenza virus vaccine live, intranasal in children 6 to \< 60 months of age. Enrollment of approximately 200 participants was stratified by age, with 100 participants 6 to \< 24 months of age (who reached their sixth month but not their second year birthday) and 100 participants 24 to \< 60 months of age (who reached their second year but not their fifth year birthday). Baseline medical history data collection included the participants prior receipt of influenza vaccine or history of laboratory-confirmed influenza illness in the previous influenza season.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single, intranasal dose of 0.2 millilitre (mL) (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 fluorescent focus units (FFU) of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
Biological: Trivalent influenza virus vaccine live, intranasal
Participants received a single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 FFU of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
Biological: Trivalent influenza virus vaccine live, intranasal
A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 FFU of three influenza virus strains.
Also known as: FluMist, Cold-adapted influenza virus vaccine, trivalent (CAIV-T), Live attenuated influenza virus (LAIV)
Percentage of Participants Who Shed Any Vaccine Virus
Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by polymerase chain reaction (PCR) based assays. Viral shedding (A/New Caledonia/20/99 \[H1N1\]; A/Wyoming/03/2003 \[H3N2\] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like\]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.
Time frame: Days 1-28 after study vaccination (up to Day 28)
Percentage of Participants Who Shed A/H1N1 Vaccine Virus
Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by PCR based assays. Viral shedding (A/New Caledonia/20/99 \[H1N1\]; A/Wyoming/03/2003 \[H3N2\] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like\]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.
Time frame: Days 1-28 after study vaccination (up to Day 28)
Percentage of Participants Who Shed A/H3N2 Vaccine Virus
Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by PCR based assays. Viral shedding (A/New Caledonia/20/99 \[H1N1\]; A/Wyoming/03/2003 \[H3N2\] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like\]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.
Time frame: Days 1-28 after study vaccination (up to Day 28)
Percentage of Participants Who Shed B Vaccine Virus
Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by PCR based assays. Viral shedding (A/New Caledonia/20/99 \[H1N1\]; A/Wyoming/03/2003 \[H3N2\] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like\]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.
Time frame: Days 1-28 after study vaccination (up to Day 28)
Duration of Any Vaccine Virus Shedding
The number of days of shedding was summarized for all participants who shed any vaccine virus.
Time frame: Days 1-28 after study vaccination (up to Day 28)
Duration of Confirmed A/H1N1 Vaccine Virus Shedding
The number of days of shedding was summarized for all participants who shed confirmed A/H1N1 strain virus.
Time frame: Days 1-28 after study vaccination (up to Day 28)
Duration of Confirmed A/H3N2 Vaccine Virus Shedding
The number of days of shedding was summarized for all participants who shed confirmed A/H3N2 strain virus.
Time frame: Days 1-28 after study vaccination (up to Day 28)
Duration of Confirmed B Vaccine Virus Shedding
The number of days of shedding was summarized for all participants who shed confirmed B strain virus.
Time frame: Days 1-28 after study vaccination (up to Day 28)
Quantitation of Confirmed A/H1N1 Shed Vaccine Virus on Any Day
Quantitation of confirmed A/H1N1 shed vaccine virus was evaluated using the log transformed median tissue culture infectious dose (TCID50) per (/) millilitre (mL) for A/H1N1 vaccine strain and summarized for all participants who shed vaccine virus.
Time frame: Days 1-28 after study vaccination (up to Day 28)
Quantitation of Confirmed A/H3N2 Shed Vaccine Virus on Any Day
Quantitation of confirmed A/H3N2 shed vaccine virus was evaluated using the log (TCID50)/mL for A/H3N2 vaccine strain and summarized for all participants who shed vaccine virus.
Time frame: Days 1-28 after study vaccination (up to Day 28)
Quantitation of Confirmed B Shed Vaccine Virus on Any Day
Quantitation of confirmed B shed vaccine virus was evaluated using the log (TCID50)/mL for B vaccine strain and summarized for all participants who shed vaccine virus.
Time frame: Days 1-28 after study vaccination (up to Day 28)
Number of Participants With Genotypic and Phenotypic Stability of A/H1N1 Shed Vaccine Virus
The genetic and phenotypic stability of shed vaccine virus was evaluated by determination of genomic sequence and assessment of the cold-adapted (ca) and temperature-sensitive (ts) phenotypes. Viruses were considered ts if their titer at 39 degrees Celsius (°C) was at least two logs (100-fold) lower than their titer at 33°C. Viruses were considered ca if they replicated at 25°C to a titer that was no more than two logs (100-fold) lower than the titer at 33°C. After additional phenotypic and genotypic analyses, all evaluable samples retained the ca and ts phenotypes.
Time frame: Days 1-28 after study vaccination (up to Day 28)
Number of Participants With Genotypic and Phenotypic Stability of A/H3N2 Shed Vaccine Virus
The genetic and phenotypic stability of shed vaccine virus was evaluated by determination of genomic sequence and assessment of the ca and ts phenotypes. Viruses were considered ts if their titer at 39°C was at least two logs (100-fold) lower than their titer at 33°C. Viruses were considered ca if they replicated at 25°C to a titer that was no more than two logs (100-fold) lower than the titer at 33°C. After additional phenotypic and genotypic analyses, all evaluable samples retained the ca and ts phenotypes.
Time frame: Days 1-28 after study vaccination (up to Day 28)
Number of Participants With Genotypic and Phenotypic Stability of B Shed Vaccine Virus
The genetic and phenotypic stability of shed vaccine virus was evaluated by determination of genomic sequence and assessment of the ca and ts phenotypes. Viruses were considered ts if their titer at 37°C was at least two logs (100-fold) lower than their titer at 33°C. Viruses were considered ca if they replicated at 25°C to a titer that was no more than two logs (100-fold) lower than the titer at 33°C. After additional phenotypic and genotypic analyses, all evaluable samples retained the ca and ts phenotypes.
Time frame: Days 1-28 after study vaccination (up to Day 28)
Number of Participants With Reactogenicity Events (REs) and Adverse Events (AEs) Through 28 Days Post Vaccination
REs were predefined solicited events that could potentially occur after vaccination. The REs for this study were fever, runny/stuffy nose, sore throat, cough, vomiting, headache, abdominal pain (stomach ache), muscle ache, chills, decreased activity level (lethargy), decreased appetite, and irritability. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Time frame: Days 0-28 after vaccination (up to Day 28)
Number of Participants With Serious Adverse Events (SAEs) and Significant New Medical Conditions (SNMC) Through 180 Days Post Vaccination
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An SNMC is defined as a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant. SNMCs included, but were not limited to, diabetes, asthma, autoimmune disease (lupus, rheumatoid arthritis), and neurological disease (epilepsy, autism).
Time frame: Days 0-180 after vaccination (up to 6.5 months)
Number of Participants With REs in Relation to Any Vaccine Virus Shedding
REs were predefined solicited events that could potentially occur after vaccination. The REs for this study were fever, runny/stuffy nose, sore throat, cough, vomiting, headache, abdominal pain (stomach ache), muscle ache, chills, decreased activity level (lethargy), decreased appetite, and irritability.
Time frame: Days 0-28 after study vaccination (up to Day 28)
A total of 200 participants were enrolled in the study from 15-May-2006 through 22-Jun-2006 at 16 sites in the United States of America.
| Milestone | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| Started | 100 | 100 |
| Completed | 98 | 99 |
| Not completed | 2 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Participant was not contacted in window | 0 | 1 |
Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by polymerase chain reaction (PCR) based assays. Viral shedding (A/New Caledonia/20/99 \[H1N1\]; A/Wyoming/03/2003 \[H3N2\] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like\]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.
| percentage of participants | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| Percentage of Participants Who Shed Any Vaccine Virus | 88.9 (81.0 to 94.3) | 69.0 (59.0 to 77.9) |
Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by PCR based assays. Viral shedding (A/New Caledonia/20/99 \[H1N1\]; A/Wyoming/03/2003 \[H3N2\] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like\]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.
| percentage of participants | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| Percentage of Participants Who Shed A/H1N1 Vaccine Virus | 76.8 (67.2 to 84.7) | 52.0 (41.8 to 62.1) |
Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by PCR based assays. Viral shedding (A/New Caledonia/20/99 \[H1N1\]; A/Wyoming/03/2003 \[H3N2\] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like\]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.
| percentage of participants | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| Percentage of Participants Who Shed A/H3N2 Vaccine Virus | 57.6 (47.2 to 67.5) | 15.0 (8.6 to 23.5) |
Viral shedding is defined as the detection of virus by viral culture and vaccine-type virus was confirmed by PCR based assays. Viral shedding (A/New Caledonia/20/99 \[H1N1\]; A/Wyoming/03/2003 \[H3N2\] (A/Fujian/411/2002-like); B/Jilin/20/2003 B/Shanghai/361/2002-like\]) was measured from samples obtained from nasal swabs daily from Days 1 to 7 post vaccination and approximately every other day thereafter from Days 9 to 28. Participants whose Day 25 or 28 shedding sample was positive for vaccine virus had additional shedding samples collected approximately every 7 days, or as soon as possible upon awareness of culture positivity, until 2 consecutive samples were negative for vaccine virus.
| percentage of participants | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| Percentage of Participants Who Shed B Vaccine Virus | 37.4 (27.9 to 47.7) | 37.0 (27.6 to 47.2) |
The number of days of shedding was summarized for all participants who shed any vaccine virus.
| days | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| Duration of Any Vaccine Virus Shedding | 3.0 ± 1.5 | 2.7 ± 1.6 |
The number of days of shedding was summarized for all participants who shed confirmed A/H1N1 strain virus.
| days | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| Duration of Confirmed A/H1N1 Vaccine Virus Shedding | 2.1 ± 1.0 | 2.2 ± 1.3 |
The number of days of shedding was summarized for all participants who shed confirmed A/H3N2 strain virus.
| days | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| Duration of Confirmed A/H3N2 Vaccine Virus Shedding | 1.8 ± 0.9 | 1.7 ± 0.8 |
The number of days of shedding was summarized for all participants who shed confirmed B strain virus.
| days | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| Duration of Confirmed B Vaccine Virus Shedding | 2.1 ± 1.5 | 1.8 ± 1.2 |
Quantitation of confirmed A/H1N1 shed vaccine virus was evaluated using the log transformed median tissue culture infectious dose (TCID50) per (/) millilitre (mL) for A/H1N1 vaccine strain and summarized for all participants who shed vaccine virus.
| log (TCID50)/mL | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| Quantitation of Confirmed A/H1N1 Shed Vaccine Virus on Any Day | 2.14 ± 0.98 | 2.62 ± 0.97 |
Quantitation of confirmed A/H3N2 shed vaccine virus was evaluated using the log (TCID50)/mL for A/H3N2 vaccine strain and summarized for all participants who shed vaccine virus.
| log (TCID50)/mL | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| Quantitation of Confirmed A/H3N2 Shed Vaccine Virus on Any Day | 1.59 ± 0.95 | 1.10 ± 0.53 |
Quantitation of confirmed B shed vaccine virus was evaluated using the log (TCID50)/mL for B vaccine strain and summarized for all participants who shed vaccine virus.
| log (TCID50)/mL | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| Quantitation of Confirmed B Shed Vaccine Virus on Any Day | 1.70 ± 1.09 | 1.24 ± 0.68 |
The genetic and phenotypic stability of shed vaccine virus was evaluated by determination of genomic sequence and assessment of the cold-adapted (ca) and temperature-sensitive (ts) phenotypes. Viruses were considered ts if their titer at 39 degrees Celsius (°C) was at least two logs (100-fold) lower than their titer at 33°C. Viruses were considered ca if they replicated at 25°C to a titer that was no more than two logs (100-fold) lower than the titer at 33°C. After additional phenotypic and genotypic analyses, all evaluable samples retained the ca and ts phenotypes.
| participants | All Participants |
|---|---|
| Genotypic Stability (n=0) | NA |
| Phenotypic Stability (n=93) | 90 |
The genetic and phenotypic stability of shed vaccine virus was evaluated by determination of genomic sequence and assessment of the ca and ts phenotypes. Viruses were considered ts if their titer at 39°C was at least two logs (100-fold) lower than their titer at 33°C. Viruses were considered ca if they replicated at 25°C to a titer that was no more than two logs (100-fold) lower than the titer at 33°C. After additional phenotypic and genotypic analyses, all evaluable samples retained the ca and ts phenotypes.
| participants | All Participants |
|---|---|
| Genotypic Stability (n=0) | NA |
| Phenotypic Stability (n=39) | 37 |
The genetic and phenotypic stability of shed vaccine virus was evaluated by determination of genomic sequence and assessment of the ca and ts phenotypes. Viruses were considered ts if their titer at 37°C was at least two logs (100-fold) lower than their titer at 33°C. Viruses were considered ca if they replicated at 25°C to a titer that was no more than two logs (100-fold) lower than the titer at 33°C. After additional phenotypic and genotypic analyses, all evaluable samples retained the ca and ts phenotypes.
| participants | All Participants |
|---|---|
| Genotypic Stability (n=33) | 33 |
| Phenotypic Stability (n=61) | 29 |
REs were predefined solicited events that could potentially occur after vaccination. The REs for this study were fever, runny/stuffy nose, sore throat, cough, vomiting, headache, abdominal pain (stomach ache), muscle ache, chills, decreased activity level (lethargy), decreased appetite, and irritability. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
| participants | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| Any REs | 84 | 77 |
| AEs | 48 | 31 |
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An SNMC is defined as a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant. SNMCs included, but were not limited to, diabetes, asthma, autoimmune disease (lupus, rheumatoid arthritis), and neurological disease (epilepsy, autism).
| participants | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| SAEs | 1 | 0 |
| SNMC | 1 | 1 |
REs were predefined solicited events that could potentially occur after vaccination. The REs for this study were fever, runny/stuffy nose, sore throat, cough, vomiting, headache, abdominal pain (stomach ache), muscle ache, chills, decreased activity level (lethargy), decreased appetite, and irritability.
| participants | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| Number of Participants With REs in Relation to Any Vaccine Virus Shedding | 75 | 55 |
Collected over AEs - Days 0-28 post dosing (up to Day 28); SAEs - Days 0-180 post dosing (up to 6.5 months). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Participants Between 6 to < 24 Months Age | — | 1/100 (1%) | 48/100 (48%) |
| Cohort 2: Participants Between 24 to < 60 Months Age | — | 0/100 (0%) | 25/100 (25%) |
| Event | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/100 | 0/100 |
| Event | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age |
|---|---|---|
| TEETHINGGastrointestinal disorders | 21/100 | 0/100 |
| DIARRHOEAGastrointestinal disorders | 5/100 | 9/100 |
| OTITIS MEDIAInfections and infestations | 4/100 | 0/100 |
| ARTHROPOD BITEInjury, poisoning and procedural complications | 4/100 | 3/100 |
| PHARYNGITIS STREPTOCOCCALInfections and infestations | 1/100 | 3/100 |
| VIRAL INFECTIONInfections and infestations | 3/100 | 2/100 |
| BODY TEMPERATURE INCREASEDInvestigations | 3/100 | 2/100 |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 3/100 | 2/100 |
| OTORRHOEAEar and labyrinth disorders | 2/100 | 0/100 |
| CONJUNCTIVITISEye disorders | 2/100 | 0/100 |
| Age, Continuous(months) | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age | Total |
|---|---|---|---|
| Mean | 14.87 ± 5.50 | 41.31 ± 9.98 | 28.09 ± 15.50 |
| Sex: Female, Male(Participants) | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age | Total |
|---|---|---|---|
| Female | 51 | 53 | 104 |
| Male | 49 | 47 | 96 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 15 | 22 |
| Not Hispanic or Latino | 93 | 85 | 178 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 14 | 7 | 21 |
| White | 86 | 89 | 175 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| History of laboratory-confirmed influenza illness in previous influenza season(participants) | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age | Total |
|---|---|---|---|
| Yes | 1 | 2 | 3 |
| No | 99 | 98 | 197 |
| History of receiving an influenza vaccine(participants) | Cohort 1: Participants Between 6 to < 24 Months Age | Cohort 2: Participants Between 24 to < 60 Months Age | Total |
|---|---|---|---|
| Yes | 43 | 73 | 116 |
| No | 57 | 27 | 84 |
Ran from May 2006 to primary completion in Jul 2006, 2 months.
Results were first posted in Nov 2010, 4 years 4 months after primary completion.
Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 2 months is below that.
Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: FluMist